Maternal parasitaemia (at delivery) · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole probably leads to lower maternal peripheral parasitaemia at delivery (PCR) compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Placental malaria · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole probably leads to lower placental malaria (PCR) compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Maternal anaemia at delivery · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole showed no clear difference in maternal anaemia at delivery compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Low birthweight · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole showed no clear difference in low birth weight compared with cotrimoxazole (moderate certainty).
1 finding from 1 review
Spontaneous abortions and stillbirths · HIV‐infected pregnant women
It is very uncertain whether mefloquine plus cotrimoxazole changes spontaneous abortions and stillbirths compared with cotrimoxazole (very low certainty).
1 finding from 1 review
Vomiting · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole leads to higher AEs: vomiting compared with cotrimoxazole (high certainty).
1 finding from 1 review
Dizziness · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole leads to higher AEs: dizziness compared with cotrimoxazole (high certainty).
1 finding from 1 review
Clinical malaria episodes during pregnancy · HIV‐infected pregnant women
Mefloquine plus cotrimoxazole showed no clear difference in clinical malaria episodes during pregnancy compared with cotrimoxazole (high certainty).
1 finding from 1 review
IRR 0.76 [0.33, 1.76]
1 study · 1 participants
High